IMR Press / EJGO / Volume 31 / Issue 3 / pii/1630985087298-1509090602

European Journal of Gynaecological Oncology (EJGO) is published by IMR Press from Volume 40 Issue 1 (2019). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with S.O.G.

Open Access Original Research
Expression of p16 in serous ovarian neoplasms
Show Less
1 Department of Pathology, Uludag University School of Medicine, Bursa
2 Department of Biostatistics, Uludag University School of Medicine, Bursa
3 Department of Gynecology and Obstetrics, Uludag University School of Medicine, Bursa (Turkey)
Eur. J. Gynaecol. Oncol. 2010, 31(3), 312–314;
Published: 10 June 2010
Abstract

Purpose: We aimed to examine p16 protein expression in ovarian serous neoplasms along with normal ovarian tissues. Materials and Methods: p16 expression was immunhistochemically evaluated in 86 ovarian serous neoplasms (21 cystadenomas, 20 borderline tumors and 45 carcinomas) and 21 non-neoplastic ovarian tissue. The results were also compared with histopathological grade in serous adenocarcinomas. Results: p16 expression rates for benign, borderline ovarian tumors and ovarian cancer were 14.2%, 85% and 86.6%, respectively. It was significantly higher in carcinomas (p < 0.001) and borderline tumors (p < 0.001) compared to cystadenomas. No immunoreactivity was found in the non-neoplastic ovarian surface epithelial cells. The percentage of p16 expression did not change significantly with histological grade in carcinomas. Conclusion: p16 expression is strong and widespread involving most tumor cells in serous papillary ovarian carcinomas, and is probably an early event.
Keywords
p16
Immunohistochemistry
Ovarian serous carcinoma
Borderline tumor
Cystadenoma
Share
Back to top